Abstract
The SARS-COV-2 pandemic led to the development of several vaccinations to contain the disease. The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine was recommended on May 2021 for use in children above 12 years and older. The vaccine is safe, well tolerated and highly effective. Initial reports showed no serious adverse events; however, cases of myocarditis in young healthy male adolescents have been reported. We report two cases of myocarditis/perimyocarditis who presented with short history of chest pain following administration of the second dose of the MRN COVID-19 vaccine.
Reference12 articles.
1. Myocarditis after vaccination against covid-19;Gellad;BMJ,2021
2. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021
3. Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations;Power;Expert Rev Cardiovasc Ther,2022
4. US Food and Drug Administration . Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. FDA news release, 2021. Available: https://www.fda.gov/news-events/press- [Accessed 22 Jun 2022].
5. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献